Maternal inheritance of familial hypercholesterolemia caused by the V408M low-density lipoprotein receptor mutation

Jorie Versmissen1, Ilse P G Botden, Roeland Huijgen

  • 1Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.

Atherosclerosis
|September 20, 2011
PubMed

Insights

Familial hypercholesterolemia (FH) inherited from mothers leads to significantly higher mortality than when inherited from fathers. This supports the fetal origin of adult disease, highlighting the need for maternal cholesterol management during pregnancy.

Area of Science:

  • Cardiovascular Genetics
  • Developmental Biology
  • Epidemiology

Background:

  • Maternal hypercholesterolemia during fetal development can increase atherosclerosis risk.
  • Familial hypercholesterolemia (FH) is an inherited condition causing high LDL cholesterol.
  • The impact of maternal vs. paternal inheritance of FH on long-term health outcomes is not fully understood.

Purpose of the Study:

  • To investigate whether the parent of origin of familial hypercholesterolemia (FH) influences mortality risk.
  • To test the hypothesis that maternal inheritance of FH is associated with more extreme CHD risk.

Main Methods:

  • Analysis of a large Dutch pedigree with a known LDL receptor gene mutation (V408M).
  • Studied 161 individuals across seven generations with known FH status and parental origin.
  • Calculated standardized mortality ratios (SMR) and used Poisson regression to compare maternal and paternal FH inheritance.

Main Results:

  • Maternal FH inheritance showed a significantly higher excess mortality (SMR 2.49) compared to paternal inheritance (SMR 1.30).
  • Relative risk of excess mortality was 2.2 for maternal inheritance (p=0.048).
  • Paternal FH inheritance did not show a statistically significant increase in mortality.

Conclusions:

  • Inheriting familial hypercholesterolemia (FH) from the mother is linked to substantially increased all-cause mortality.
  • Findings support the fetal origin of adult disease hypothesis, emphasizing prenatal influences on atherosclerosis.
  • Further research is needed on safe cholesterol-lowering therapies for pregnant women with FH to mitigate adverse epigenetic effects in offspring.
Abstract

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...